Improved Formulation of $^{224}$Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP

Ruth Gong Li $^{1,2,3,*}$, Kim Lindland $^1$, Sandra Karen Tonstad $^1$, Tina Bjørnlund Bønsdorff $^1$, Asta Juzeniene $^3$, Sara Westrom $^1$ and Roy Hartvig Larsen $^1$

1 Oncoinvent AS, 0484 Oslo, Norway; lindland@oncoinvent.com (K.L.); tonstad@oncoinvent.com (S.K.T.); bonsdorff@oncoinvent.com (T.B.B.); westrom@oncoinvent.com (S.W.); scienccons@gmail.com (R.H.L.)
2 Institute of Clinical Medicine, University of Oslo, 0316 Oslo, Norway
3 Department of Radiation Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, 0379 Oslo, Norway; asta.juzeniene@rr-research.no
* Correspondence: li@Oncoinvent.com

Abstract: Radium-224-labeled CaCO$_3$ microparticles have been developed to treat peritoneal carcinoma. The microparticles function as carriers of $^{224}$Ra, facilitating intraperitoneal retention of the alpha-emitting radionuclide. It was necessary to control the size of microparticles in suspension over time and introduce a sterilization process for the clinical use of the radiopharmaceutical. Ethylenediamine tetra(methylene phosphonic acid) (EDTMP) was investigated as a stabilizing additive. The possibility of encapsulating the radionuclides with an outer surface layer of CaCO$_3$ for the improved retention of radioactivity by the carrier was studied. This work evaluated these steps of optimization and their effect on radiochemical purity, the biodistribution of radionuclides, and therapeutic efficacy. An EDTMP concentration of $>$1% ($w/w$) relative to CaCO$_3$ stabilized the particle size for at least one week. Without EDTMP, the median particle size increased from $\sim$5 µm to $\sim$25 µm immediately after sterilization by autoclaving, and the larger microparticles sedimented rapidly in suspension. The percentage of adsorbed $^{224}$Ra progeny $^{212}$Pb increased from 56% to 94% at 2.4–2.5% ($w/w$) EDTMP when the $^{224}$Ra-labeled microparticles were layer-encapsulated. The improved formulation also resulted in a suitable biodistribution of radionuclides in mice, as well as a survival benefit for mice with intraperitoneal ovarian or colorectal tumors.

Keywords: radiopharmaceutical; radionuclide therapy; alpha therapy; alpha emitter; calcium carbonate; microparticles; radium; peritoneal carcinomatosis

1. Introduction

Effective treatment of cancers with peritoneal dissemination by cytoreductive surgery is challenging because of the presence of residual tumor cells and micrometastases. The eradication of small intraperitoneal (i.p.) tumors and single cells can be achieved through the use of highly energetic and short-range alpha radiation in combination with a carrier compound that facilitates i.p. containment of the radioactive payload. Radium-224-labeled calcium carbonate microparticles ($^{224}$Ra-CaCO$_3$ MPs) in suspension were developed according to this concept $^1$, and their therapeutic potential was evaluated in mice with i.p. ovarian cancer $^2$–$^4$. As a medically promising alpha-emitter, $^{224}$Ra is a radionuclide with a convenient half-life of 3.6 days. It has more than 90% of its decay energy associated with alpha emissions; $^{224}$Ra and its progenies emit four alpha particles in total (Figure 1). Further, $^{224}$Ra can be adsorbed by CaCO$_3$ MPs, which are suitable carriers because CaCO$_3$ is nontoxic and biodegradable. We previously demonstrated the importance of the CaCO$_3$ MPs as a carrier compound by comparing $^{224}$Ra-CaCO$_3$ MPs to free radium-$^{224}$ dichloride ($^{224}$RaCl$_2$) when both were administered i.p. The $^{224}$Ra-CaCO$_3$ MPs resulted in increased...
i.p. retention of $^{224}$Ra [1] and extended the survival of mice with tumors [3]. This radiopharmaceutical (Radspherin) is currently being tested in two ongoing clinical phase I trials, as a postoperative treatment to combat the remaining micrometastatic tumors following the complete cytoreductive surgery of peritoneal carcinomatosis originating from ovarian and colorectal cancer [5,6].

One important factor in terms of product stability during the 7-day shelf-life of the radiopharmaceutical is preserving the particle size. The particle size itself influences the ability of MPs to remain suspended, as larger particles settle faster. Calcium carbonate can exist in three different crystalline polymorphs: vaterite, aragonite, and calcite. These different forms have characteristic morphologies: vaterite is typically present as spherical particles, aragonite as needle-like structures, and calcite as rhombohedral particles [7,8]. The thermodynamic stability of the polymorphs also varies; calcite is the only stable form. The dissolution and subsequent reprecipitation of CaCO$_3$ in aqueous solution, a process known as recrystallization, causes a transformation from metastable vaterite or aragonite to stable calcite [9]. Moreover, recrystallization causes the growth of individual CaCO$_3$.
particles. Larger particles grow at the expense of dissolving smaller ones, in a process known as Ostwald ripening [10,11], or the smaller particles may aggregate into larger particles [11]. This leads to increasing particle diameter with time, especially at elevated temperature [11]. Therefore, additives that inhibit recrystallization are necessary to control the size of $^{224}$Ra-CaCO$_3$ MPs, which ensures a stable and dispersed suspension of MPs over time.

Various compounds ranging from small molecules to (bio)polymers have been reported to influence the morphology of CaCO$_3$ crystals, e.g., by inhibiting recrystallization [7,10,12,13], and therefore, have a stabilizing effect on crystal structure and/or size. Among these, phosphonic acid derivatives, or phosphonates, are interesting candidates. In relation to CaCO$_3$, these compounds have been used in industrial water management to prevent scale formation attributed to CaCO$_3$ precipitating on surfaces [14]. It has been proposed that the phosphonates inhibit CaCO$_3$ nucleation, adsorb to and block crystal growth sites, distort the crystal lattice, and change the surface charge of crystals [14,15]. The phosphonate ethylenediamine tetra(methylene phosphonic acid) (EDTMP) can retard the transformation from vaterite to calcite [16]. Furthermore, the calcium binding property of phosphonates can be exploited therapeutically due to their consequent skeletal accumulation in diseases such as osteoporosis, where bone resorption by osteoclasts is inhibited by bisphosphonates [17].

Phosphonates have strong chelation properties toward many divalent metal ions, including radiometals [18]. Therefore, in combination with their skeletal targeting, phosphate-based radiopharmaceuticals have been developed to both diagnose and relieve pain from skeletal metastases [18]. Samarium lexidronam ($^{153}$Sm-EDTMP) is approved worldwide for the pain relief of osteoblastic metastatic bone lesions. While radium itself is inherently a bone-seeker, EDTMP has been used to increase the proportion of daughter nuclides $^{212}$Pb and $^{212}$Bi delivered to the bone in mouse models [19,20]. However, if the goal is to ensure radionuclide accumulation at other target sites, the complexation and bone-seeking properties may be problematic. In our application, the CaCO$_3$ MPs retain $^{224}$Ra and progeny, reducing the extraperitoneal release of $^{224}$Ra and therefore, the level of $^{224}$Ra in the skeleton [1]. For any stabilizing additive, its influence on the ability of CaCO$_3$ MPs to retain radionuclides, i.e., radiochemical purity (RCP), must be clarified.

The aim of this work was to evaluate the crystal growth inhibitor and chelator EDTMP as an additive in suspensions of $^{224}$Ra-CaCO$_3$ MPs in order to determine both its ability to stabilize the particle size during the shelf-life of the product and any potential negative effect on RCP, the in vivo biodistribution of radionuclides, or therapeutic efficacy.

2. Materials and Methods

2.1. Producing $^{224}$Ra-CaCO$_3$ MPs

Calcium carbonate MPs were produced by spontaneous precipitation according to a previously reported procedure [1,3,21], with the exception of the drying process; the collected precipitate was dried under vacuum at 100 °C for 1 h. Radiolabeling was also performed as described earlier [3], with a few modifications. Radium-224 was extracted from a generator consisting of $^{228}$Th (Oak Ridge National Laboratory, Oak Ridge, TN, USA) that was either immobilized on a TrisKem Actinide Resin (TrisKem International, Bruze, France) and eluted in 1 M HCl (Suprapur, Merck Group, Darmstadt, Germany) or temporarily immobilized on a Dowex anion exchange resin (Sigma-Aldrich, St. Louis, MO, USA) and then eluted in 0.5 M HNO$_3$ (PlasmaPURE Plus, SCP Science, Baie-d’Urfé, QC, Canada) and 80% methanol (Merck Group, Darmstadt, Germany) before evaporation to dryness, which was followed by dissolution in 1 M HCl. In the latter case, the dissolved residue was run through a TrisKem Actinide Resin. In both cases, 5 M NH$_4$OAc (Sigma-Aldrich, St. Louis, MO, USA) and 1 M NaOH (VWR International, Radnor, PA, USA) were added to obtain a pH of 7.5–9 in the final $^{224}$RaCl$_2$ solution to be used for radiolabeling. The $^{224}$RaCl$_2$ solution was sterile filtered prior to labeling. The CaCO$_3$ MPs were surface-labeled with $^{224}$Ra by incubation in the $^{224}$RaCl$_2$ solution (0.1–2.7 kBq per mg of CaCO$_3$).
in the presence of Ba\(^{2+}\) (0.004\% (w/w) relative to CaCO\(_3\)) and SO\(_4^{2-}\) (0.6\% (w/w) relative to CaCO\(_3\)) for the coprecipitation of \(^{224}\)Ra. The labeled MPs were then washed once with 0.9\% NaCl (Fresenius Kabi AG, Bad Homburg, Germany) before any addition of EDTMP (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) and final suspension in 0.9\% NaCl.

A modified layer-encapsulated \(^{224}\)Ra-CaCO\(_3\) MP was prepared by adding an outer CaCO\(_3\) layer after labeling in an effort to encapsulate its radioactivity. Calcium carbonate microparticles were first surface-labeled as described earlier. After the removal of the incubation solution, equimolar amounts of Na\(_2\)CO\(_3\) and CaCl\(_2\) (Merck Group, Darmstadt, Germany) were added to the labeled MPs under vigorous stirring. This led to an additional precipitation process on the surface of the MPs that would increase the total precipitated CaCO\(_3\) mass by a factor of 2.2–2.4, corresponding to a 30–33\% increase in the MP diameter, assuming precipitation exclusively took place on the surface of existing MPs. In some cases, additional Ba\(^{2+}\) and SO\(_4^{2-}\) were added during the precipitation process to account for the increase in total CaCO\(_3\) mass to final relative concentrations of 0.004\% (w/w) and 0.6\% (w/w), respectively. The encapsulated and labeled MPs were washed once with 0.9\% NaCl before EDTMP was added, and the MPs were suspended in 0.9\% NaCl.

In some cases, where radioactivity was deemed unimportant for the study outcome, CaCO\(_3\) MPs were either suspended directly in saline ("unlabeled") or mock-labeled. As for the unlabeled MPs, mock-labeling resulted in a nonradioactive suspension of CaCO\(_3\) MPs but involved the same preparation steps and reagents as for the radiolabeled and layer-encapsulated MPs, except for the use of 0.9\% NaCl in place of a solution of \(^{224}\)RaCl\(_2\).

In all cases, the MPs were suspended in 0.9\% NaCl, sealed in a crimp neck glass headspace vial, and sterilized in an autoclave at 121 \(\degree\)C for 20 min. The suspension cooled to room temperature before further handling.

The remaining sections will distinguish surface-labeled MPs from layer-encapsulated MPs for clarity, despite the fact that both were surface-labeled initially.

2.2. Particle Size Measurements

The size of unlabeled, mock-labeled, and radiolabeled CaCO\(_3\) MPs in suspension with varying concentrations of EDTMP was measured with laser diffraction (Mastersizer 3000, Malvern Instruments Ltd., Worcestershire, UK). The unautoclaved CaCO\(_3\) MPs used as raw material for radio- and mock-labeling were used as a reference by dispersing a small amount of dried CaCO\(_3\) MPs in water and ultrasonicating to disperse. Size stability over time was evaluated in radiolabeled CaCO\(_3\) MPs by measuring after seven days of storage at room temperature; surface-labeled MPs were compared with layer-encapsulated MPs.

2.3. Influence of EDTMP on the Sedimentation Rate of MPs

The ability of MPs to remain suspended in solution was evaluated by the sedimentation rate, which was investigated through the visual inspection of samples and by evaluating the turbidity of different suspensions of nonradioactive mock-labeled CaCO\(_3\) MPs, with and without EDTMP. Turbidity was assessed by diluting the CaCO\(_3\) MP suspension with water (water for injection) and then measuring the change in optical density at a wavelength of 800 nm over 30 min using a spectrophotometer (Hitachi U-1900, Hitachi High-Tech, Tokyo, Japan). The 800 nm wavelength was chosen to reduce potential light absorbance by CaCO\(_3\) and improve light scattering by particles. A decrease in optical density with time is, therefore, directly related to decreased light scattering by MPs and thereby, decreased turbidity of the sample due to sedimentation.

2.4. Influence of EDTMP on Radiochemical Properties

The intrinsic product stability of \(^{224}\)Ra-CaCO\(_3\) MPs during shelf-life was assessed by measuring the radiochemical purity and comparing surface-labeled MPs to layer-encapsulated MPs. Radiochemical purity was defined as the percentage of radionuclides retained on the MPs after a certain period. A small aliquot of suspension was separated into MP fraction P and supernatant fraction S by centrifugation. The percentage radio-
chemical purity, % RCP, was defined as the proportion of radioactivity in the P fraction: CPM(P)/CPM(P+S), with CPM denoting counts per minute. The radioactivity of the two fractions was measured separately using a Hidex Automatic Gamma Counter (Hidex Oy, Turku, Finland). Sample tubes with air-tight lids were used to avoid potential Rn escape from the samples [4]. Radioactivity of 212Pb was quantified by counts in the 60–110 keV window [22]. For 224Ra, radioactivity was determined indirectly by assuming a transient equilibrium between 224Ra and progeny 212Pb after allowing the two fractions to decay for at least two days and then measuring 212Pb activity in the 65–345 keV window, in which gamma energy and X-rays mainly originated from this daughter. Sampling and measurement were repeated after up to seven days of storage at room temperature to evaluate the stability of 212Pb and 224Ra % RCP over time.

The complexation between the released 212Pb from MPs and EDTMP in the solution was evaluated in the liquid phase of different variants of 224Ra-CaCO3 MPs. The liquid fraction was first separated from the MPs by centrifugation. The degree of 212Pb-EDTMP complexation in the obtained supernatant was then measured using instant thin-layer chromatography (ITLC) strips (Tec-Control Chromatography Systems #150-772, Biodex Medical Systems, Inc., Shirley, NY, USA). Chelated 212Pb will migrate with the mobile phase in this system, while most (>90%) unbound 212Pb2+ will remain at the origin line, allowing for the evaluation of 212Pb-EDTMP complexation. Water (pharmaceutical grade) or 0.9% NaCl was used as the mobile phase, and the strips were cut in half after the solvent front had reached the top line. The radioactivity of 212Pb in the two parts was measured with a Hidex Automatic Gamma Counter as described earlier. The degree of chelation was defined by the proportion of migrated 212Pb in the liquid fraction of 224Ra-CaCO3 MPs and was quantified by subtracting the unspecific migration of free 212Pb2+ in a 0.9% NaCl solution without EDTMP. Equation (1) describes the percentage chelation; A212Pb-EDTMP denotes the measured activity in the supernatant of 224Ra-CaCO3 MPs; A212Pb,denotes the measured activity of free 212Pb2+ in the 0.9% NaCl solution, and m and o denote the two parts of the ITLC strip; m denotes migration with the mobile phase and o denotes the origin line.

\[
% \text{chelation} = \left( \frac{A_{212\text{Pb-EDTMP}, m}}{A_{212\text{Pb-EDTMP}, m} + A_{212\text{Pb-EDTMP}, o}} - \frac{A_{212\text{Pb}, m}}{A_{212\text{Pb}, m} + A_{212\text{Pb}, o}} \right) \times 100\% \tag{1}
\]

2.5. Biodistribution

The biodistribution of layer-encapsulated 224Ra-CaCO3 MPs with added EDTMP was evaluated in institutionally bred nontumor-bearing female athymic nude mice (Hsd: Athymic Nude-Foxn1nu, Department of Comparative Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway). Calcium carbonate microparticles were labeled and autoclaved as described earlier. The impact of mass dose (mg dose) was considered by testing doses ranging from 1–12 mg CaCO3 and 6–18 kBq by creating dilutions with an isotonic infusion solution (Plasmalyte, Baxter International Inc., Deerfield, IL, USA). One day after a single i.p. administration, the mice were euthanized by cervical dislocation, and tissue samples were obtained to measure radioactivity. Three standard samples corresponding to 25–50% of the administered dose of each treatment were used to determine the injected radioactivity dose. The radioactivity of 212Pb and 224Ra of tissue and standard samples was measured using a gamma counter as described above, from which the percentage injected dose per gram tissue (% ID/g) was calculated. Correction for decay and/or ingrowth of 224Ra and 212Pb was not performed in the calculation of the % ID/g for two reasons: firstly, standard samples and tissue samples were counted with less than 2–3 h time interval (i.e., 3% of the half-life of 224Ra), and secondly, error propagation as a result of uncertainty in the measurement of 224Ra, when the measured activity was close to or below the limit of quantification of the instrument, could be avoided. As a reference for the skeletal accumulation of free 224Ra2+ one day after i.p. injection, one group of mice received ~30 kBq 224RaCl2 prepared as described previously [3]. An overview of the experimental groups is provided in Supplementary Table S1.
2.6. Therapeutic Efficacy

The therapeutic effect of radiolabeled MPs of different sizes with $^{224}$Ra adsorbed either on the surface or beneath an outer protective layer was evaluated. Layer-encapsulated $^{224}$Ra-CaCO$_3$ MPs suspended in EDTMP (1% (w/w) relative to CaCO$_3$) and 0.9% NaCl solution were compared to that of the surface-labeled variant suspended in 0.9% NaCl only, by evaluating the survival rate of mice with tumors. To establish i.p. ovarian cancer xenografts, nude mice aged 4–5 weeks were inoculated with 1 million ES-2 cells (ATCC, Germany) [2–4]. For a syngeneic colorectal cancer model, BALB/c mice (BALB/cAnNRj, Janvier Labs, Le Genest-Saint-Isle, France) aged six weeks were inoculated i.p. with 50,000 CT26.WT cells (LGC Standards, ATCC, Wesel, Germany) in a study managed by Minerva Imaging (Ølstykke, Denmark). In both cases, mice were randomized and received a single i.p. injection of autoclaved $^{224}$Ra-CaCO$_3$ MPs (14–26 kBq, 4–14 mg), or 0.9% NaCl as vehicle control, one day after tumor inoculation. The dosing was selected based on previously tested efficacious doses with former generations of unautoclaved $^{224}$Ra-CaCO$_3$ MPs in the ES-2 model [2–4]. An overview of the experimental groups can be found in Supplementary Table S2. Animals were supplied with food and water ad libitum and euthanized by cervical dislocation when reaching predetermined study endpoints, which included rapid body weight loss or severe build-up of ascites. Animals were censored if they lived beyond the timepoint corresponding to three times the median survival time of the longest surviving group.

2.7. Statistical Analysis

A statistical analysis of the differences between the experimental groups in the animal studies was performed with GraphPad Prism (Version 8.1.2, GraphPad Software, San Diego, CA, USA). A t-test was performed on each pair of experimental groups in the biodistribution study to detect differences in the % ID/g while adjusting the obtained p-value to account for multiple comparisons using the Holm–Sidak method. In the studies of therapeutic efficacy, differences in the survival curves were analyzed using the Gehan–Breslow–Wilcoxon method while adjusting the obtained p-values using the Holm–Sidak method. In both cases, an adjusted p < 0.05 was considered statistically significant.

3. Results

3.1. Stabilization of Microparticle Size; Influence of EDTMP and Layer Encapsulation

As an additive, EDTMP was studied with the purpose of obtaining size control over $^{224}$Ra-CaCO$_3$ MPs. When no EDTMP was present, the median (volume-based) diameter of MPs increased from 5 µm in the raw material to 25 µm immediately after autoclaving (day zero) of the suspension but remained stable for at least five days thereafter (Figure 2a, Table 1). A concentration of 0.1% (w/w) EDTMP relative to CaCO$_3$ was able to retain the size of MPs on day zero, however, five days later, the median diameter had grown to 18 µm. A concentration of 1% (w/w) EDTMP relative to CaCO$_3$ was necessary to stabilize the MP size for at least five days. This concentration resulted in a slight shift of the size distribution to a smaller size as compared with the CaCO$_3$ MPs used as raw material; this is because of the improved dispersion of the suspension.

The EDTMP concentration of 1% (w/w) relative to CaCO$_3$ retained the size of autoclaved surface $^{224}$Ra-labeled CaCO$_3$ MPs for at least seven days, with no change in particle diameter when the concentration was increased to 12% (w/w) (Figure 2b, Table 1).

For the autoclaved layer-encapsulated MPs that were either surface-labeled with $^{224}$Ra or mock-labeled, a minimum EDTMP concentration of 2.4% (w/w) relative to CaCO$_3$ was necessary to disperse MPs in the autoclaved suspension in these experiments. The size remained stable for at least seven days, and increasing the EDTMP concentration to 12% (w/w) did not influence MP size (Figure 2c, Table 1). A minor population of submicrometer particles was detected, suggesting that the process of layer encapsulation causes the formation of a small volume of new particles in addition to creating layers on pre-existing particles. The direct comparison of the surface-labeled MPs with the encapsulated MPs, with or without EDTMP, showed a slight shift in the particle size distribution towards the smaller size.
ones showed that both the 50th and 90th percentile of MP-size increased by ~20% on average ($n = 4$) at 2.4–2.5% (w/w) EDTMP, which supports the formation of an outer layer of CaCO$_3$ on the radiolabeled MPs (Figure 2d, Table 1).

**Figure 2.** Size distribution of CaCO$_3$ microparticles. (a) Unlabeled, nonradioactive CaCO$_3$ MPs suspended in saline and autoclaved on day zero with varying EDTMP % (w/w) compared with the unautoclaved CaCO$_3$ MPs used as raw material. (b) Surface $^{224}$Ra-labeled CaCO$_3$ MPs with varying EDTMP % (w/w) compared with the unautoclaved CaCO$_3$ MPs used as raw material. (c) Autoclaved and layer-encapsulated $^{224}$Ra surface-labeled CaCO$_3$ MPs with varying EDTMP % (w/w) compared with the unautoclaved CaCO$_3$ MPs used as raw material. (d) Comparison of surface-labeled and layer-encapsulated surface-labeled MPs, excerpts from (b,c) Dv: volumetric diameter, with Dv10 being the 10th percentile, etc.
Table 1. Size distribution of various CaCO₃ MPs from Figure 2, shown as the volumetric 10th percentile (Dv10), 50th percentile (Dv50), and 90th percentile (Dv90). Day 0 refers to the day of preparing the sample including autoclaving of all samples with the exception of the raw material. na: not applicable.

| Compound | EDTMP Concentration (w/w)% | Particle Size Distribution (Dv10/Dv50/Dv90) on Day 0 (µm) | Particle Size Distribution (Dv10/Dv50/Dv90) on Day 5 or 7 (µm) |
|----------|-----------------------------|------------------------------------------------------------|------------------------------------------------------------|
| CaCO₃ MP raw material (1) | 0 | 2.5/5.0/9.6 | na |
| CaCO₃ MPs (1) | 0 | 12.2/24.7/44.5 | 12/24.2/43.3 |
| CaCO₃ MPs (1) | 0.1% | 2.7/6.5/19.6 | 7.5/18.3/32.8 |
| CaCO₃ MPs | 1% | 2.0/3.9/6.8 | 2.2/3.9/6.7 |
| CaCO₃ MP raw material (2) | 0 | 2.8/5.7/10.3 | na |
| Surface-labeled ²²⁴Ra-CaCO₃ MPs (2) | 1.2% | 2.4/4.7/9.3 | 2.4/4.6/8.8 |
| Surface-labeled ²²⁴Ra-CaCO₃ MPs (2,4) | 2.4% | 2.4/4.6/8.6 | 2.4/4.7/8.9 |
| Surface-labeled ²²⁴Ra-CaCO₃ MPs (2) | 12% | 2.4/4.6/8.6 | 2.4/4.5/8.3 |
| CaCO₃ MP raw material (3) | 0 | 2.8/5.7/10.3 | na |
| Layer-encapsulated ²²⁴Ra-CaCO₃ MPs (3) | 2.4% | 2.4/5.8/10.8 | 2.9/5.9/9.9 |
| Layer-encapsulated ²²⁴Ra-CaCO₃ MPs (3,4) | 12% | 2.6/5.7/10.2 | 2.5/5.7/10.7 |

(1) Size distribution shown in Figure 2a, (2) size distribution shown in Figure 2b, (3) size distribution shown in Figure 2c, (4) size distribution shown in Figure 2d.

When EDTMP was present at 2.4–2.5% (w/w), the smaller CaCO₃ MPs (median diameter of 5–6 µm) remained suspended for a considerably longer time compared to CaCO₃ MPs without EDTMP (median diameter of 25–26 µm); this was visible with the naked eye immediately after the suspensions were autoclaved (Figure 3a). The large difference in the sedimentation rate between samples with and without EDTMP was also detected in a turbidity assessment (Figure 3b). Little variation was observed for MPs suspensions with EDTMP, but the measurement indicated a slightly increased sedimentation rate of the layer-encapsulated MPs compared to the surface-labeled MPs between 10 and 30 min (Figure 3b).

A light microscope showed that EDTMP preserved the spherical morphology of CaCO₃ MPs after autoclaving, as the MPs would otherwise recrystallize into cuboid structures (Supplementary Figure S1).

3.2. Radiochemical Properties Depending on EDTMP and Layer Encapsulation

The decay of ²²⁴Ra results in ²¹²Pb, which is known to form a complex with EDTMP [19,20]. For this reason, it was suspected that the presence of EDTMP could influence the fraction of ²¹²Pb adsorbed on CaCO₃ MPs (% RCP) versus released ²¹²Pb in the liquid phase. For a given EDTMP concentration in the suspension of ²²⁴Ra-CaCO₃ MPs, % RCP on the same day as labeling (day zero) was highest for the layer-encapsulated MP variant when compared to surface-labeled MPs in all cases. For both variants, there was a trend of decreasing RCP with increasing EDTMP concentration (Figure 4a). Increased ²¹²Pb % RCP was observed for surface-labeled MPs from day zero to day four for all of the tested EDTMP concentrations, indicating the readsorption of ²¹²Pb from decayed ²²⁴Ra. However, the % RCP remained relatively stable for the layer-encapsulated MPs, though with the highest value on day zero (Figure 4a). The % RCP of ²²⁴Ra appeared unaffected by the
outer CaCO₃ layer on MPs, but a higher fraction of radionuclides remained on both MP variants for the two lowest EDTMP concentrations (Figure 4b). The RCP remained stable for at least seven days; there was no detectable difference between the two MP variants for a given EDTMP concentration for ²²⁴Ra (Figure 4b).

Radioactivity measurements of ITLC strips were performed to evaluate the degree of complexation between unbound ²¹²Pb²⁺ and EDTMP in the liquid phase of ²²⁴Ra-CaCO₃ MPs, correcting for unspecific migration by ²¹²Pb²⁺ in 0.9% NaCl. The analysis revealed that the fraction of chelated ²¹²Pb increased for EDTMP concentrations ≥5% (w/w) as compared to 2.4–2.5% (w/w) and remained stable for at least one week (Figure 4c). The significance of the layer encapsulation was only visible at the lowest EDTMP concentration of 2.4–2.5% (w/w) with 0–4% chelation, compared to 63–73% chelation in the surface-labeled variant.

3.3. Biodistribution of Layer-Encapsulated ²²⁴Ra-CaCO₃ MPs with EDTMP

The biodistribution of 1–12 mg layer-encapsulated ²²⁴Ra-CaCO₃ MPs with 1.2–2.5% (w/w) EDTMP relative to CaCO₃ was evaluated one day after i.p. administration in mice. A significant decrease in % ID/g of both ²²⁴Ra and ²¹²Pb in the femur and skull was observed for all of the tested doses (p < 0.0050) as compared to i.p. administration of free ²²⁴Ra²⁺ (Figure 5a,b, Supplementary Table S3). Varying the mass dose had little effect on biodistribution, apart from a decrease in skeletal % ID/g of ²²⁴Ra when injecting 12 mg as compared to 1 mg (p < 0.0075, Supplementary Table S3). Low or modest levels of ²¹²Pb were detected in the skeleton at all tested ²²⁴Ra-CaCO₃ MP doses (Figure 5b). Variability in the % ID/g in the i.p. fat was attributed to a technical difficulty when removing small MP residues from these tissue samples.
Figure 4. Radiochemical analysis of adsorbed $^{212}\text{Pb}$ and $^{224}\text{Ra}$ on CaCO$_3$ microparticles (MPs) with varying EDTMP concentrations. Symbols represent independent samples and EDTMP concentration is relative to CaCO$_3$. (a) Percentage of adsorbed $^{212}\text{Pb}$ (% RCP) on the MPs on different days after labeling, surface-labeled MPs vs layer-encapsulated surface-labeled MPs. (b) Percentage of adsorbed $^{224}\text{Ra}$ on the MPs (% RCP) on different days after labeling, surface-labeled MPs vs layer-encapsulated surface-labeled MPs. (c) Percentage of $^{212}\text{Pb}$-EDTMP in the liquid phase after subtracting unspecific migration by $^{212}\text{Pb}^{2+}$ in 0.9% NaCl in the ITLC setup on different days after labeling, surface-labeled MPs vs layer-encapsulated surface-labeled MPs.

3.4. Influence on Therapeutic Efficacy by Particle Size, Layer Encapsulation, and EDTMP

The effect of the MP size and layer-encapsulation of radiolabeled MPs on therapeutic efficacy was assessed in mice with i.p. xenograft ovarian cancer or i.p. syngeneic colorectal cancer. Layer-encapsulated $^{224}\text{Ra}$-CaCO$_3$ MPs with 1% (w/w) EDTMP relative to CaCO$_3$ and a median diameter of 7–9 µm were compared with a surface-labeled variant without EDTMP added and a median diameter of 9–23 µm. The latter resembled the $^{224}\text{Ra}$-CaCO$_3$ MPs reported previously [3], apart from the terminal sterilization by autoclaving, which was not performed in previous work. A survival benefit was observed in both tumor models when they were treated with the two formulations as compared to the control group (Figure 6, Supplementary Table S4, highest $p$-values: $p = 0.0068$ for the ES-2 model and $p = 0.044$ for CT26.WT). The two variants performed almost equally in terms of median...
survival time in both tumor models (27 and 29 days for ES-2, 27 and 33 days for CT26.WT). Hence, no statistical difference was observed between the two $^{224}\text{Ra}$-CaCO$_3$ MP treatments ($p = 0.4477$ for ES-2, $p = 0.6331$ for CT26.WT). All animals were euthanized exclusively at disease-related endpoints, including ascites development and/or palpable tumors.

Figure 5. Biodistribution of layer-encapsulated $^{224}\text{Ra}$ surface-labeled CaCO$_3$ microparticles one day after i.p. injection. Bars represent the median and symbols represent individual animals. Animals that were treated with equal or near-equal mass doses have been pooled into one group. (a) Percentage injected dose per gram tissue of $^{224}\text{Ra}$. (b) Percentage injected dose per gram tissue of $^{212}\text{Pb}$ from the same samples as in (a). There is missing data for $^{224}\text{Ra}$ and $^{212}\text{Pb}$ for one skull in the $^{224}\text{RaCl}_2$ group and for $^{212}\text{Pb}$ for one blood sample in the 12 mg group due to instrument errors.

Figure 6. Therapeutic effect of $^{224}\text{Ra}$-labeled microparticles; surface-labeled microparticles vs layer-encapsulated surface-labeled microparticles. (a) Kaplan–Meier curves of nude mice inoculated with ES-2 cells on day zero. (b) Kaplan–Meier curves of BALB/c mice inoculated with CT26.WT cells on day zero. There are censored mice on day 99, corresponding to three times the median survival time of the longest surviving group at which the study was terminated; one mouse is censored on the black and grey curves while two mice are censored on the blue curve.
4. Discussion

This work has shown that the size of $^{224}$Ra-CaCO$_3$ MPs in suspension can be stabilized for at least one week by adding the recrystallization inhibitor EDTMP to the suspension and that the percentage of the daughter nuclide $^{212}$Pb retained on the MPs can be increased by an outer encapsulating CaCO$_3$ surface layer.

Additives that inhibit recrystallization are necessary to prevent the growth of CaCO$_3$ MPs in suspension, while the particle size itself is important for the MP to remain suspended. The present work considered only autoclaved suspensions of MPs, contrasting with our previously published work on the $^{224}$Ra-CaCO$_3$ MPs [1–4], because a sterilization procedure is compulsory for a radiopharmaceutical intended for clinical use. The growth of CaCO$_3$ MPs with no EDTMP added was detected immediately after the suspension was autoclaved. Even though the increased particle diameter remained stable thereafter, the particles sedimented fast and the suspension was difficult to disperse. The size distribution of CaCO$_3$ MPs remained constant from unlabeled raw material to radiolabeled MPs in suspension when EDTMP was added. It is important to note that the sedimentation rate was substantially reduced when the particle size was decreased and that the smaller MPs were easier to disperse and handle, resulting in a significant advantage in terms of clinical administration of the product.

After obtaining size control via EDTMP, layer encapsulation was introduced to optimize the radiochemical properties of the $^{224}$Ra-CaCO$_3$ MPs, as EDTMP is known to chelate $^{212}$Pb and other divalent metals [18–20]. The presence of an outer CaCO$_3$ layer on CaCO$_3$ MPs that had already been surface-labeled was supported by comparing their size distribution to that of CaCO$_3$ MPs that were only surface-labeled. The slight increase in MP diameters from the surface-labeled analog did not influence their ability to disperse. However, the additional precipitation process resulted in the formation of a small volume of submicrometer CaCO$_3$ particles that could only be detected after layer-encapsulation.

It was suspected that complexation of $^{212}$Pb with EDTMP would result in a decrease in MP-bound $^{212}$Pb, which could potentially lead to the undesired release of $^{212}$Pb to systemic circulation in vivo and localization of $^{212}$Pb-EDTMP to the skeleton. The largest difference between surface-labeled and layer-encapsulated $^{224}$Ra-CaCO$_3$ MPs with EDTMP was detected in their ability to retain $^{212}$Pb. At 2.4–2.5% (w/w) EDTMP relative to CaCO$_3$, the $^{212}$Pb % RCP of layer-encapsulated $^{224}$Ra-CaCO$_3$ MPs was highest on day zero (94%) and remained above 79% on average over the course of seven days. The cumulative amount of the chemically equivalent stable daughter nuclide $^{208}$Pb (Figure 1) adsorbed on the MPs increases with time (Supplementary Figure S2), although this seems to have little effect on the adsorption of $^{212}$Pb. For the surface-labeled variant at this EDTMP concentration, % RCP of $^{212}$Pb was only 56% on day zero, with an increase to 70% on day four. The increased adsorption of $^{212}$Pb from day zero to day four was a general observation for surface-labeled MPs. For both MP variants, the persistence of adsorbed $^{212}$Pb over time is a result of either retention of $^{224}$Ra daughters after decay, reassociation of released $^{212}$Pb, or a combination of the two. We have previously shown that a certain emanation of the gaseous $^{220}$Rn, the parent of $^{212}$Pb, occurs from $^{224}$Ra-CaCO$_3$ MPs, with $^{212}$Pb being substantially readsorbed by the MPs [4]. For the optimized formulation herein, readsorption may also be mediated by EDTMP, as released $^{212}$Pb$^{2+}$ is sequestered by EDTMP at sufficient EDTMP concentration. The known complexation property of EDTMP with both $^{212}$Pb and calcium indicates that it is also possible for the $^{212}$Pb-EDTMP complex to associate with the MPs. To test this hypothesis, adsorption of $^{212}$Pb on nonradioactive mock-labeled CaCO$_3$ MPs, both with and without layer-encapsulation, was evaluated after the addition of a solution of $^{212}$Pb-EDTMP. It was found that 17–20% of the $^{212}$Pb-EDTMP adsorbed on the MPs; the adsorption increased to 96% when unbound $^{212}$Pb$^{2+}$ (1$^{212}$PbCl$_2$) was added instead (Supplementary Figure S3). The reduced adsorption of $^{212}$Pb-EDTMP is in line with the general observation that the % RCP of $^{212}$Pb of both surface-labeled MPs and layer-encapsulated MPs decreased at higher EDTMP concentrations in the MP suspension. The exact distribution of EDTMP in solution versus on the MPs themselves is not known,
although it can be argued that the majority is adsorbed on the MPs due to the low presence of chelated $^{212}$Pb in solution for the layer encapsulated $^{224}$Ra-CaCO$_3$ MPs with 2.4–2.5% (w/w) EDTMP (Figure 4c).

The stable particle size in combination with the promising radioactivity-retention properties of the layer-encapsulated $^{224}$Ra-CaCO$_3$ MPs with low EDTMP concentration warranted further investigation in animal models. A suitable biodistribution pattern of both $^{212}$Pb and $^{224}$Ra was achieved after i.p. administration at 1.2–2.5% (w/w) EDTMP. The substantially decreased % ID/g of both $^{212}$Pb and $^{224}$Ra detected in the skeleton when compared with i.p. injection of $^{224}$RaCl translates to low levels of radionuclides leaking from the peritoneal cavity. The slightly higher skeletal activity for the 1 mg dose as compared to 5–12 mg is attributed to the difference in specific activity, i.e., activity per CaCO$_3$ mass (1–1.8 kBq/mg vs. ~6 kBq/mg), which is in line with previous work [1, 3]. Low levels of $^{212}$Pb were detected in the skeleton as compared to the previously published biodistribution results of $^{212}$Pb-EDTMP after i.v. administration to mice [19], indicating a limited release of any potential $^{212}$Pb-EDTMP to systemic circulation. The localization of EDTMP to bone is attributed to its affinity to hydroxyapatite and is dependent on calcium concentration rather than the number of osteoblasts [23]. Hence, the presence of Ca$^{2+}$ from CaCO$_3$ may possibly contribute to retaining EDTMP on MPs within the peritoneal cavity, at least within the relatively short half-lives of $^{224}$Ra and its daughters.

The loading of radionuclides into carrier MPs for tumor radiotherapy is an approach that has historically been used for beta emitters. [24]. For alpha emitters, the incorporation of the nuclide into the bulk of the carrier can be advantageous as a means of retaining recoiling daughter nuclides to prevent unintentional escape and redistribution in vivo. Incorporation of alpha emitters such as $^{225}$Ra/$^{225}$Ac, and/or $^{223}$Ra into nanoparticles has been reported in liposomes [25, 26], LaPO$_4$ [27], LaVO$_4$ [28] and hydroxyapatite [29], among others. Further, a study of $^{225}$Ac-labeled CaCO$_3$ MPs was recently published, with the $^{225}$Ac incorporated into MPs and submicron particles that were coated with a protein and polyphenol on the particle surface as stabilizing agents [30]. Ensuring that the encapsulation does not compromise the already short range of the alpha particles (50–100 µm in tissue) is a prerequisite for alpha emitters to be carried inside MPs. The MP size and the thickness of the encapsulating layer of $^{223}$Ra-CaCO$_3$ MPs are both very small compared to the range of alpha particles and are therefore not expected to significantly limit the range. However, size-dependent sedimentation differences may potentially affect the distribution of the infused microparticles. In this work, the data from studies of mice with tumors was inconclusive in terms of the potential influence of particle size and EDTMP on survival. A survival benefit in mice was observed in two different tumor models after a single i.p. injection, but no statistical difference was detected when the smaller layer-encapsulated $^{224}$Ra-CaCO$_3$ MPs with EDTMP were compared to the larger surface-labeled $^{224}$Ra-CaCO$_3$ MPs without EDTMP.

Ongoing clinical studies (NCT03732768 [5], NCT03732781 [6]) with $^{224}$Ra-CaCO$_3$ MPs (Radspherin) have been initiated on the basis of the promising preclinical data on layer-encapsulated $^{224}$Ra-CaCO$_3$ MPs with 1.2–2.5% (w/w) EDTMP added.

5. Conclusions

To summarize, we have optimized $^{224}$Ra-CaCO$_3$ MP formulation to achieve a suitable product for clinical usage. The addition of EDTMP stabilizes size over time, thereby increasing the ability of MPs to remain suspended, which is important for ease of handling during administration of the product to patients. The layer-encapsulation of the radionuclide MPs and the addition of 2.4–2.5% (w/w) EDTMP relative to CaCO$_3$ provide suitable radiochemical and biodistribution properties of the radionuclides. The optimized $^{224}$Ra-CaCO$_3$ MPs had a therapeutic effect in the tumor models presented here; antitumor efficacy was not affected by the modification.
6. Patents

The presented technology is covered by “Radiotherapeutic particles and suspensions”, patent number US9539346 B1. The privately held company Oncoinvent AS holds intellectual property rights.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/pharmaceutics13050634/s1, Supplementary Table S1: Overview of the experimental groups used in the biodistribution study of layer-encapsulated 224Ra surface-labeled CaCO₃ microparticles with EDTMP added to control the size of microparticles, Supplementary Table S2: Overview of the experimental groups used in the study of the therapeutic efficacy of 224Ra-labeled CaCO₃ microparticles, comparing the surface-labeled microparticles without EDTMP with the layer-encapsulated surface-labeled microparticles with added EDTMP, Supplementary Table S3: Summary of p-values in the biodistribution study obtained by performing a t-test on each pair of experimental groups, Supplementary Table S4: Summary of p-values in the two studies of therapeutic efficacy obtained from the Gehan–Breslow–Wilcoxon method, Supplementary Figure S1: Photomicrographs of CaCO₃ microparticles, Supplementary Figure S2: Distribution of 208Pb and 212Pb on layer-encapsulated microparticles with 2.5% (w/w) EDTMP as a function of days after labeling with 224Ra, Supplementary Figure S3: Percentage adsorption of 212Pb²⁺ and 212Pb-EDTMP to nonradioactive mock-labeled CaCO₃ MPs, surface-labeled MPs, and layer-encapsulated surface-labeled MPs.

Author Contributions: Conceptualization, R.H.L., S.K.T., T.B.B., and R.G.L.; methodology, R.H.L. and S.K.T.; validation, A.J. and T.B.B.; formal analysis, R.G.L. and A.J.; investigation, R.G.L., K.L., S.K.T., and S.W.; resources, T.B.B. and S.W.; data curation, T.B.B.; writing—original draft preparation, R.G.L., and A.J.; writing—review and editing, R.H.L., T.B.B., A.J., R.G.L., S.W., K.L., and R.H.L.; visualization, R.G.L.; supervision, T.B.B., R.H.L., S.W.; project administration, T.B.B.; funding acquisition, T.B.B. and R.H.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Norwegian Research Council under grant numbers 282220 and 291228, and Oncoinvent AS.

Institutional Review Board Statement: All procedures with experimental animals were approved by the Institutional Committee on Research Animal Care (Department of Comparative Medicine, Oslo University Hospital, Norway), the Norwegian Food Safety Authority, and/or the National Animal Experiments Inspectorate under the Ministry of Environment and Food of Denmark. Animal experiments performed in Norway were approved under the project number 9884 on 29 September 2016. The animals were treated in accordance with institutional, national, and EU regulations on the use of research animals.

Informed Consent Statement: Not applicable.

Data Availability Statement: The reported data is available from Oncoinvent AS, although there are restrictions on its availability under the license of the presented work, and it is not publicly available. However, data is available from the authors upon reasonable request and with the permission of Oncoinvent AS.

Acknowledgments: We would like to thank Minerva Imaging for performing the therapeutic efficacy study in the CT26.WT model. We also thank Kristin Fure and Solveig Wulff for providing 224RaCl₂ for the experiments presented herein, and Ida Sofie Jorstad, Marion Malenge, and Elisa Napoli for their support in the planning, design, and/or execution of the experimental work. Lastly, we thank Michael Dornish for developing and sharing the method for assessing turbidity.

Conflicts of Interest: The authors declare the following conflicts of interest: R.G.L., K.L., S.K.T., T.B.B., and S.W. are employed at the privately held Norwegian company Oncoinvent A.S., and R.H.L. is the chairman of the board of the company. K.L., T.B.B., S.W., and R.H.L. own stock in Oncoinvent AS.

References
1. Westrøm, S.; Malenge, M.; Jorstad, I.S.; Napoli, E.; Bruland, Ø.S.; Bønsdorff, T.B.; Larsen, R.H. Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice. J. Labelled. Compd. Radiopharm. 2018, 61, 472–486. [CrossRef] [PubMed]
2. Westrøm, S.; Bønsdorff, T.B.; Bruland, Ø.S.; Larsen, R.H. Therapeutic effect of α-emitting 224Ra-labeled calcium carbonate microparticles in mice with intraperitoneal ovarian cancer. Trans. Oncol. 2018, 11, 259–267. [CrossRef] [PubMed]
3. Li, R.; Napoli, E.; Jorstad, I.; Bønsdorff, T.; Jużeniene, A.; Bruland, Ø.; Larsen, R.H.; Westrøm, S. Calcium carbonate microparticles as carriers of $^{224}$Ra: Impact of specific activity in mice with intraperitoneal ovarian cancer. *Curr. Radiopharm.* 2021, 14. [CrossRef]

4. Napoli, E.; Bønsdorff, T.B.; Jorstad, I.S.; Bruland, Ø.S.; Larsen, R.H.; Westrøm, S. Radon-220 diffusion from $^{224}$Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use. *PLoS ONE* 2021, 16, e0248133. [CrossRef] [PubMed]

5. National Library of Medicine (US). ClinicalTrials.gov. Identifier NCT03732768. Study of Radospherin in Recurrent Ovarian Cancer Subjects with Peritoneal Carcinomatosis. Available online: https://clinicaltrials.gov/ct2/show/NCT03732768 (accessed on 30 November 2020).

6. National Library of Medicine (US). ClinicalTrials.gov. Identifier NCT03732781. Study of Radospherin in Colorectal Carcinoma Subjects with Peritoneal Carcinomatosis Treated with HIPEC. Available online: https://clinicaltrials.gov/ct2/show/NCT03732781 (accessed on 30 November 2020).

7. Boyjoo, Y.; Pareek, V.K.; Liu, J. Synthesis of micro and nano-sized calcium carbonate particles and their applications. *J. Mater. Chem. A* 2014, 2, 14270–14288. [CrossRef]

8. Ševčík, R.; Šašek, P.; Viani, A. Physical and nanomechanical properties of the synthetic anhydrous crystalline CaCO$_3$ polymorphs: Vaterite, aragonite, and calcite. *J. Mater. Sci.* 2018, 53, 4022–4033. [CrossRef]

9. Ogino, T.; Suzuki, T.; Sawada, K. The formation and transformation mechanism of calcium carbonate in water. *Geochim. Cosmochim. Acta* 1987, 51, 2757–2767. [CrossRef]

10. Lakshtanov, L.Z.; Belova, D.A.; Okhrimenko, D.V.; Stipp, S.L.S. Role of alginate in calcite recrystallization. *Cryst. Growth Des.* 2015, 15, 419–427. [CrossRef]

11. Schultz, L.N.; Dideriksen, K.; Lakshtanov, L.; Hakim, S.S.; Mütter, D.; Bechgaard, K.; Stipp, S.L.S. From nanometer to micrometer: a potential alpha-particle-emitting cancer therapeutic agent. *Anticancer Res.* 2016, 36, 1661–1667. [CrossRef]

12. Didymus, J.M.; Oliver, P.; Mann, S.; DeVries, A.L.; Hauschka, P.V.; Westbroek, P. Influence of low-molecular-weight and macromolecular organic additives on the morphology of calcium carbonate. *J. Chem. Soc. Faraday Trans.* 1993, 89, 2891. [CrossRef]

13. Matahwa, H.; Ramiah, V.; Sanderson, R.D. Calcium carbonate crystallization in the presence of modified polysaccharides and biological extracts. *Pure Appl. Chem.* 1997, 69, 921–928. [CrossRef]

14. Nowack, B. Environmental chemistry of phosphonates. *Water Res.* 2003, 37, 2533–2546. [CrossRef]

15. Reddy, M.M.; Nancollas, G.H. Calcite crystal growth inhibition by phosphonates. *J. Chem. Soc. Faraday Trans.* 2003, 99, 1032–1045. [CrossRef]

16. Sawada, K. The mechanisms of crystallization and transformation of calcium carbonates. *Pure Appl. Chem.* 2008, 80, 4561–4569. [CrossRef]

17. Drake, M.T.; Clarke, B.L.; Khosla, S. Bisphosphonates: Mechanism of action and role in clinical practice. *Mayo Clin. Proc.* 2008, 83, 1032–1045. [CrossRef]

18. Lange, R.; Heine, R.; Knapp, R.; Klerk, J.M.H.; Bloemendal, H.J.; Hendrikse, N.H. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. *Bone* 2016, 91, 159–179. [CrossRef]

19. Hassfjell, S.P.; Hoff, P.; Bruland, Ø.S.; Alstad, J. $^{212}$Pb/$^{212}$Bi-EDTMP—Synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical. *J. Labelled. Compd. Radiopharm.* 1994, 34, 717–734. [CrossRef]

20. Jużeniene, A.; Bernoulli, J.; Suominen, M.; Halleen, J.; Larsen, R.H. Antitumor activity of novel bone-seeking, $\alpha$-emitting $^{224}$Ra-solution in a breast cancer skeletal metastases model. *Anticancer Res.* 2018, 38, 1947–1955. [CrossRef]

21. Volodkin, D.V.; Petrov, A.I.; Prevot, M.; Sukhorukov, G.B. Matrix polyelectrolyte microcapsules: New system for macromolecule encapsulation. *Langmuir* 2004, 20, 3398–3406. [CrossRef]

22. Napoli, E.; Stenberg, V.Y.; Juzeniene, A.; Hjellum, G.E.; Bruland, Ø.S.; Larsen, R.H. Calibration of sodium iodide detectors and reentrant ionization chambers for $^{212}$Pb activity in different geometries by HPGe activity determined samples. *Appl. Radiat. Isot.* 2020, 166, 109362. [CrossRef]

23. Toegel, S.; Hoffmann, O.; Wadsak, W.; Ettingler, D.; Mien, L.K.; Wiesner, K.; Nguemo, J.; Viervest, H.; Kletter, K.; Dudačzak, R.; et al. Uptake of bone-seekers is solely associated with mineralisation! A study with $^{99m}$Tc-MDP, $^{153}$Sm-EDTMP and $^{18}$F-fluoride on osteoblasts. *Eur. J. Nucl. Med.* 2006, 33, 491–494. [CrossRef]

24. Hamoudeh, M.; Kamleh, M.A.; Diab, R.; Fessi, H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. *Adv. Drug Deliv. Rev.* 2008, 60, 1329–1346. [CrossRef]

25. Henriksen, G.; Schoutz, B.W.; Michaelsen, T.E.; Bruland, Ø.S.; Larsen, R.H. Sterically stabilized liposomes as a carrier for $\alpha$-emitting radium and actinium radionuclides. *Nucl. Med. Biol.* 2004, 31, 441–449. [CrossRef]

26. Jonasdottir, T.J.; Fisher, D.R.; Borrebaek, J.; Bruland, Ø.S.; Larsen, R.H. First in vivo evaluation of liposome-encapsulated $^{223}$Ra as a potential alpha-particle-emitting cancer therapeutic agent. *Anticancer Res.* 2006, 26, 2841–2848. [CrossRef]

27. Rojas, J.V.; Woodward, J.D.; Chen, N.; Rondinone, A.J.; Castano, C.H.; Mirzadeh, S. Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for $^{223}$Ra and $^{225}$Ra for targeted alpha therapy. *Nucl. Med. Biol.* 2015, 42, 614–620. [CrossRef]

28. Toro-González, M.; Peacock, A.; Miskowiec, A.; Cullen, D.A.; Copping, R.; Mirzadeh, S.; Davern, S.M. Tailoring the radionuclide encapsulation and surface chemistry of La ($^{223}$Ra) VO$_4$ nanoparticles for targeted alpha therapy. *J. Nanotheranostics* 2021, 2, 33–50. [CrossRef]
29. Kozempel, J.; Vlk, M.; Málková, E.; Bajžíková, A.; Bárta, J.; Santos-Oliveira, R.; Rossi, A.M. Prospective carriers of $^{223}$Ra for targeted alpha particle therapy. *J. Radioanal. Nucl. Chem.* **2015**, *304*, 443–447. [CrossRef]

30. Muslimov, A.R.; Antuganov, D.; Tarakanchikova, Y.V.; Karpov, T.E.; Zhukov, M.V.; Zyuzin, M.V.; Timin, A.S. An investigation of calcium carbonate core-shell particles for incorporation of $^{225}$Ac and sequester of daughter radionuclides: In vitro and in vivo studies. *J. Control. Release* **2021**, *330*, 726–737. [CrossRef]